阿斯利康提出需求:在大多数的慢性肾脏疾病的情况下有关肾小球滤过屏障功能受损的研究。缺少良好的肾小球体外模型,就不能在细胞学和病理学的范畴详细理解肾小球的功能。 阿斯利康正在寻找方法来开发一个肾小球模型系统。理想情况下,体外模型应该包含一个独立的微型药学单元,有适当的介质,流体流动和所受压力。可以调整模拟体内黏膜所需条件属性,最终建立形成一个功能肾小球滤过屏障。 具体看下面内容: https://www.innocentive.com/ar/challenge/9933748The majority of all cases of chronic kidney disease, a key research area within AstraZeneca, originate in the glomerulus when filtration barrier function is compromised. However, a detailed cellular understanding of the functioning and pathology of the glomerulus has been limited by the lack of good in vitro models of glomerular function. AstraZeneca is looking for approaches to develop a glomerular model system. Ideally, the in vitro model should incorporate a self-contained microphysiological unit where biologically appropriate media, fluid flow and shear stress can be modulated to simulate in vivo properties that will ultimately recapitulate the conditions necessary for endothelial and podocyte cell types to form a functional glomerular filtration barrier. This is an ideation challenge and only requires a written solution. Source: InnoCentive Challenge ID: 9933748 Challenge Overview The majority of all cases of chronic kidney disease, a key research area within AstraZeneca, originate in the glomerulus when filtration barrier is compromised. The coordinated efforts of the podocytes and endothelium together with their underlying basement membrane establish the glomerular filtration barrier and injury to these cells can lead to loss of kidney function. There are currently no human in vitro models that mimic a functional or diseased glomerulus. Development of a human glomerular filtration barrier biomimetic system will thus address gaps in in vitro models for simulating human kidney disease, toxicity and DMPK. We are looking for innovative approaches to developing a glomerular model that incorporates a self-contained microphysiological unit, ideally including podocytes, the endothelium, and where biologically appropriate media, fluid flow, and shear stress can be modulated to simulate in vivo properties that will ultimately recapitulate the structural and cellular conditions necessary for glomerular function. ABOUT THE SEEKER AstraZeneca is a global, research-based, biopharmaceutical company with a focus on five key therapeutic areas: 1) cardiovascular & metabolic diseases, 2) oncology, 3) respiratory, inflammation & autoimmunity, 4) neuroscience, and 5) infection. As an innovation-driven, research organization, AstraZeneca recognizes that great ideas come from many sources. Open innovation is an avenue by which ideas can be shared and AstraZeneca recently launched a pavilion to further its commitment to facilitate the advancement of pharmaceutical research.
当前为付费需求,赏金分配方式:一人独享赏金。
任务主在众多备选稿件中选择最满意的稿件,支付赏金。
任务主把所发需求的悬赏金托管到药智网指定账户,以激发众多药智客的参与热情,保障任务主尽快征集到满意稿件;
同时,赏金托管也是为了保障参与挑战的药智客的正当权益。
点击“发布需求”按钮,按照流程引导,将需求详情、具体要求描述清楚,发布到药智网的药智汇平台。
为征集到满意稿件,任务主须做好“赏金预算”,并将赏金托管到药智网指定账户,打消药智客的顾虑,激励药智客积极参与需求挑战。
任务主托管赏金后,所发布的需求显示“赏金已托管”字样。只有托管了悬赏金的需求,能够鼓舞众多的药智客参与,获取到满意的稿件!
任务主在众多参与者提交的稿件中,选择符合任务主需求的稿件。再通过互动,选择任务主最满意的稿件,并确定其为中标稿件。
中标稿件提交任务主验收。任务主在验收/验证期内,完成验收/验证工作。对合格稿件,通知药智网支付佣金。
双方可以针对本次交易各自的表现进行评价,评价结果将影响各自的信用度和能力值。
关于我们| 联系我们| 企业资质| 诚聘英才| 友情链接| 帮助中心| 媒体报道| 药智论坛| 全站导航| 用户体验提升计划 业务介绍
互联网增值电信业务许可证编号:渝B2-20120028 | 渝ICP备10200070号 互联网药品信息服务资格证:(渝)-经营性-2016-0011 渝公网备:50010801500236
康洲大数据 版权所有 Copyright © 2009-2019 药智网YAOZH.COM All Rights Reserved. 法律顾问:上海锦天城(重庆)律师事务所 程建律师
客户服务热线:400-678-0778 E-mail:service@yaozh.com 商务合作QQ:845146016
渝公网安备 50010802001068号
投诉热线: 02362308742
邮箱: tousu@yaozh.com
QQ: 914894005